Introduction
============

Sex hormone-binding globulin (SHBG) is a circulating glycoprotein composed of 373 amino acids and 3 carbohydrate chains that can bind to dihydrotestosterone, testosterone and estradiol, especially C18 or C19 and 17-β-hydroxyl groups. SHBG regulates plasma clearance and the uptake of sex hormones ([@b1-ol-0-0-11549]). High SHBG expression levels theoretically decrease the uptake of sex hormones. Notably, only a small percentage (\<2%) of steroids are unbound in plasma, and the remainder are primarily bound to SHBG and albumin ([@b2-ol-0-0-11549]). Therefore, SHBG may influence the carcinogenesis and progression of hormone-dependent types of cancer, such as prostate, ovary and breast cancer ([@b3-ol-0-0-11549]--[@b5-ol-0-0-11549]). There are conflicting reports regarding the association between serum levels of SHBG and the risk of prostate cancer development ([@b3-ol-0-0-11549],[@b4-ol-0-0-11549]). Grasso *et al* ([@b5-ol-0-0-11549]) identified that the plasma SHBG expression levels in patients with prostate cancer were higher compared with those with benign hyperplasia or healthy volunteers. Moreover, circulating SHBG expression levels are higher in patients with lymph node invasion ([@b6-ol-0-0-11549]) and poor differentiation ([@b7-ol-0-0-11549]). In a previous prospective study of lung cancer development, there were no significant difference in the mean concentration of sex hormones or SHBG between patients who had lung cancer and those who did not have lung cancer ([@b8-ol-0-0-11549]). However, another previous study identified that SHBG concentration was also higher in patients with lung cancer ([@b9-ol-0-0-11549]).

Intracellular SHBG has been reported in liver, placenta, endometrial, breast and prostate cancers ([@b7-ol-0-0-11549]--[@b10-ol-0-0-11549]). Steroid-free SHBG can bind to the cell membrane and once bound, SHBG can bind to steroids with equal affinity as it does in the serum. This interaction is closely associated with estrogen sensitivity to each cell ([@b11-ol-0-0-11549]). Binding of estradiol to SHBG ultimately results in breast cancer cell apoptosis and growth suppression. Therefore, SHBG serves a protective role in the exposure of breast cells to estrogen ([@b12-ol-0-0-11549]).

The SHBG expression levels in healthy postmenopausal females has been reported to be lower compared with premenopausal females, although the difference was not statistically significant ([@b13-ol-0-0-11549]). In patients aged 50--64 years, a decline of 10% was observed in SHBG expression levels compared with premenopausal females ([@b14-ol-0-0-11549]). In patients aged \>65 years, SHBG expression levels returned to the pre-menopause level ([@b14-ol-0-0-11549]). SHBG expression levels were lower in patients with breast cancer compared with in controls ([@b15-ol-0-0-11549]). In pre-menopausal patients with breast cancer, the SHBG binding capacity is in the normal range; however, it is decreased in post-menopausal patients with breast cancer ([@b16-ol-0-0-11549]--[@b18-ol-0-0-11549]). The free fraction of estradiol is increased while SHBG exhibits relative or absolute decrement in post-menopausal patients with breast cancer ([@b19-ol-0-0-11549]). It has been suggested that different critical expression levels of SHBG must be determined for pre-menopause and post-menopausal females because the mean SHBG expression levels in these two groups differ ([@b20-ol-0-0-11549]). Murayama *et al* ([@b20-ol-0-0-11549]) identified that plasma expression levels of SHBG in postmenopausal patients with ER-positive breast cancer are higher compared with patients with ER-negative breast cancer. On the contrary, there was a considerable overlap of plasma SHBG expression levels between patients with estrogen receptor (ER)^+^ and ER^−^ endometrial and cervical cancer ([@b13-ol-0-0-11549]). The major beneficial effect of tamoxifen is that it can block estrogen at the receptor level and decrease the level of biologically active estradiol by upregulating SHBG expression ([@b21-ol-0-0-11549]). However, there was no significant association between SHBG expression level and treatment response in patients with breast cancer ([@b22-ol-0-0-11549],[@b23-ol-0-0-11549]). Lymph node metastasis and histological status in patients with high SHBG expression levels are similar to patients with low SHBG expression levels ([@b24-ol-0-0-11549]). The recurrence rate between high- and low-SHBG expression level groups was not significantly different and although the high SHBG group had longer disease-free survival times, this difference was not significant in premenopausal patients with breast cancer ([@b20-ol-0-0-11549]).

In the present study, SHBG reference range was determined based on sex and age (by decade) of healthy male and female volunteers. The serum SHBG expression levels of breast cancer exhibited a different trend compared to healthy female volunteers by age decade comparison.

Patients and methods
====================

### Collection of blood specimens

Peripheral blood samples were obtained from healthy volunteers (40 males and 40 females) at Inha University Hospital (Incheon, Republic of Korea) subsequent to obtaining approval, if no laboratory (routine blood test, liver function test and tumor markers) and imaging (plain X-ray and CT scan) abnormalities were observed during the regular medical check-up. Blood samples from 34 female patients with breast cancer were obtained at 109 different time points and grouped as follow: i) Group A, non-tumor state after surgery (n=37); ii) Group B, localized tumor at diagnosis and during pre-operative chemotherapy (n=32); and iii) Group C, systemic metastasis (n=40) ([Fig. 1](#f1-ol-0-0-11549){ref-type="fig"}). Patients with locally advanced breast cancers with clinical stage III with normal laboratory findings planned for pre-operative chemotherapy were enrolled. The median age was 40 years (range, 25--66 years) for the 40 healthy males, 34 years (range, 21--56 years) for the 40 healthy female volunteers and 45 years (range, 32--65 years) for the 34 female patients with breast cancer. Median follow-up duration was 14 months (range 2--48 months). The blood samples were stored at −80°C. Heparinized vacuum tubes and needles (BD Biosciences) were used to avoid platelet damage and venous occlusion, as in the clinical setting.

### Determination of the normal range of serum SHBG

With 40 healthy male and 40 healthy female volunteer blood samples, the normal cut-off expression levels of SHBG were defined as the mean ±2 standard deviations (21--69 nmol/l) ([@b25-ol-0-0-11549]). Serum SHBG expression levels were considered positive when SHBG expression levels were out of this reference range (\>69 nmol/l, elevated; \<21 nmol/l, decreased). Patients aged ≥50 years were defined as post-menopause ([@b26-ol-0-0-11549]).

### ELISA

A sandwich ELISA was performed to measure SHBG, cancer antigen (CA)15-3 and CA125 expression levels according to the manufacturer\'s instructions. Goat polyclonal antibody kit specific for SHBG (cat. no. M-0700; 1:50; Alpha Diagnostic Intl., Inc.) and monoclonal antibody kits specific for CA15-3 (cat. no. IS-F3329; 1:100; LifeSpan Biosciences, Inc.) and CA125 (cat. no. CA239T; 1:100; Calbiotech, Inc.) were used to coat 96-well microplates. Each blood sample was added to the plate and incubated for 1 h at room temperature. Following washing 3 times with wash buffer from the kit to remove unbound proteins, enzyme-linked antibodies in each kit specific for SHBG, CA15-3 and CA125 were added to wells and incubated for 1 h at room temperature and the absorbance was measured at 450 nm. A standard curve was constructed by plotting absorbance values versus SHBG, CA15-3 and CA125 concentrations of the standards. Concentrations in the test samples were determined using this standard curve. All samples were run in triplicate. The detection limit of SHBG was 0.2 nmol/l. Intra- and inter-assay variations of SHBG were 4.3--8.5 and 7.3--11.5%, respectively. The dilution linearity was 102% (range 96--108%). The upper normal range was 25 IU/ml for CA15-3 and 35 IU/ml for CA125.

### Statistical analysis

The data were presented as mean ± standard deviation. The Shapiro-Wilk test was performed to determine whether variables were normally distributed or not. An independent t-test was used to compare differences between two groups when variables were normally distributed, while Wilcoxon rank-sum tests were performed for non-normally distributed variables. One-way analysis of variance (ANOVA) with Bonferroni post-hoc analysis was used to examine differences for normally distributed variables among three groups or more. If the normality assumption was violated, Kruskal-Wallis with Dunn\'s post-hoc test was performed instead. The correlation between variables was estimated using Spearman\'s rank correlation coefficient. P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses and graphing were performed using SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA) and R version 3.6.1. ([@b27-ol-0-0-11549],[@b28-ol-0-0-11549]).

Results
=======

### Healthy volunteers and patients with breast cancer

The median age of healthy female volunteers was younger compared with healthy males (P=0.027) or patients with breast cancer (P\<0.001; [Fig. 2](#f2-ol-0-0-11549){ref-type="fig"}). A total of 109 samples were obtained from patients with breast cancer in 3 different disease states (Group A, non-tumor state after surgery, n=37; Group B, localized tumor at diagnosis and during neo-adjuvant chemotherapy, n=32; and Group C, systemic metastasis, n=40) during a long-term follow-up ([Fig. 1](#f1-ol-0-0-11549){ref-type="fig"}).

### Comparison of SHBG expression levels with sex and age in healthy volunteers

The mean expression levels of SHBG in male and female healthy volunteers were 29.0±11.6 and 46.4±12.8 nmol/l, respectively. The SHBG expression levels were significantly higher in females compared with males (P\<0.0001; [Fig. 3A](#f3-ol-0-0-11549){ref-type="fig"}). The difference in SHBG expression levels due to sex was compared in healthy volunteer subgroups stratified by age; the difference between sexes was maintained in people aged \<30, 30--39 and ≥50 years, but not in the age group of 40--49 years ([Fig. 3B](#f3-ol-0-0-11549){ref-type="fig"}) ([Table I](#tI-ol-0-0-11549){ref-type="table"}). In men, SHBG expression levels increased until the age of 49 and then decreased (P=0.01). In females, SHBG expression levels decreased until the age of 49. An increasing pattern in females ≥50 years was identified, which was not a statistically significant difference (P=0.66; [Fig. 3B](#f3-ol-0-0-11549){ref-type="fig"}) ([Table I](#tI-ol-0-0-11549){ref-type="table"}). In females, there was no significant difference in the SHBG expression levels between the pre-menopause group \<50 years and the post-menopause group ≥50 years (46.2±13.2 vs. 48.3±8.8 nmol/l; P=0.74; [Table II](#tII-ol-0-0-11549){ref-type="table"}) ([Fig. 3C](#f3-ol-0-0-11549){ref-type="fig"}).

### SHBG expression levels in patients with breast cancer

Although there was a trend of increasing SHBG expression levels with larger tumor volumes, there was no statistically significant difference (P=0.86) in the SHBG expression levels between the 3 different tumor states: Group A (n=37), 47.3±23.7 nmol/l; Group B (n=32), 49.1±32.2 nmol/l; and Group C (n=40), 51.4±29.0 nmol/l ([Fig. 3D](#f3-ol-0-0-11549){ref-type="fig"}). SHBG expression levels were compared by age in patients with breast cancer regardless of cancer state, and these levels exhibited a decreasing trend which revealed an increasing trend in healthy females ([Fig. 4A](#f4-ol-0-0-11549){ref-type="fig"}). SHBG expression levels were compared by age between the 3 groups; there was no significant difference in Group A by age; however, Groups B and C exhibited a decrease in expression in the ≥50 years groups ([Fig. 4B](#f4-ol-0-0-11549){ref-type="fig"}). SHBG expression levels were compared between pre-menopause and post-menopause groups; the SHBG expression level exhibited a decreasing trend in post-menopausal patients compared with pre-menopausal patients, in all three groups ([Table III](#tIII-ol-0-0-11549){ref-type="table"}; [Fig. 4C](#f4-ol-0-0-11549){ref-type="fig"}).

### Comparison of serum SHBG positivity in each decade of age in breast cancer

Using a cut-off point of the mean ±2 standard deviations for SHBG positivity, a sensitivity of 36%, a specificity of 65% and an accuracy of 46% were identified. For the pre-menopause group, the sensitivity, specificity and accuracy were 44, 60 and 50%, respectively. In the post-menopause group, the sensitivity, specificity and accuracy were 26, 71 and 42%, respectively. When the sensitivity and specificity in each decade were evaluated in whole breast cancers, the sensitivity and specificity were as follows: 35 and 54% for age 30--39 years; 52 and 71% for age 40--49 years; and 26 and 71% for age ≥50 years, respectively ([Table IV](#tIV-ol-0-0-11549){ref-type="table"}).

### Comparison of serum positivity among SHBG, CA15-3 and CA125 in breast cancer

In 109 samples with different states of breast cancer, sensitivity, specificity and accuracy of CA15-3 and CA125 were simultaneously compared ([Table V](#tV-ol-0-0-11549){ref-type="table"}). Sensitivity increased when considering CA15-3 and CA125 together (75%). The highest sensitivity (79%) was obtained when all three markers were used. When SHBG was measured alongside CA15-3 or CA125 (64%), no benefit was identified regarding accuracy with CA15-3 or CA125 (70%) ([Table V](#tV-ol-0-0-11549){ref-type="table"}). CA15-3 and CA125 levels were moderately correlated with each other (r^2^=0.54; P\<0.0001; data not shown). However, both CA15-3 (r^2^=0.07; P=0.59) and CA125 (r^2^=−0.18; P= 0.17) serum levels were not significantly correlated with SHBG ([Fig. 5A and B](#f5-ol-0-0-11549){ref-type="fig"}, respectively).

Discussion
==========

SHBG is a circulating glycoprotein that binds dihydrotestosterone, testosterone and estradiol; notably, its highest binding affinity is for dihydrotestosterone and testosterone, with a lower affinity for estradiol ([@b1-ol-0-0-11549]). As a result, an increase in SHBG serum concentration may result in lowering the percentage of unbound dihydrotestosterone, testosterone and estradiol ([@b2-ol-0-0-11549]). Therefore, SHBG may be a useful predictor of circulating total and bioavailable sex hormone levels ([@b2-ol-0-0-11549]). By contrast to healthy females, to the best of our knowledge, there has been no analysis of the SHBG expression levels in healthy males. As revealed by the present data, although there was a difference in age distribution of male to female volunteers, healthy males exhibited a lower range of SHBG expression levels compared with healthy females by age (decade of age). This indicates that different normal reference values of SHBG expression levels for males and females are needed to determine abnormal expression levels of SHBG for risk evaluation of cancer or for cancer status prediction. In males, the SHBG expression levels increased from 30 to 49 years of age and then decreased ≥50 years, at which age the incidence of prostate cancer typically increases ([@b3-ol-0-0-11549]). This pattern was reversed in females who exhibited a decreasing trend until 49 years. SHBG expression levels increased in patients aged \>50 years, when the incidence of breast cancer typically increases ([@b15-ol-0-0-11549],[@b23-ol-0-0-11549]).

There is controversy regarding the association between the serum levels of SHBG and the risk of prostate cancer development, which may come from fixed normal reference value regardless of sex and age. In a Japanese population, SHBG expression levels were not strongly associated with the risk of prostate cancer, except in males age \<60 years ([@b3-ol-0-0-11549]). However, a previous study in Spain identified that low bioavailability of testosterone levels and high SHBG expression levels were associated with a 4.9- and 3.2-fold increase in the risk of prostate cancer, respectively ([@b4-ol-0-0-11549]). In localized prostate cancer, the preoperative serum SHBG expression levels were associated with prostatic extension and Gleason score ([@b29-ol-0-0-11549]). SHBG was not considered a biomarker for high-grade disease ([@b30-ol-0-0-11549]). For future prostate cancer studies, normal reference values of SHBG should reflect sex and age. In lung cancer which is non-endocrine cancer, the typical negative correlation between SHBG expression levels and total dihydrotestosterone observed in healthy volunteers and other endocrinological gynecology cancer was reversed, perhaps due to the systemic manifestation of thyrotoxicosis, chronic liver disease and disseminated cancer associated with liver metastasis ([@b8-ol-0-0-11549],[@b9-ol-0-0-11549]). In patients with cancer, different reference ranges by age, sex, cancer type (endocrinological versus non-endocrinological) and cancer stage (localized versus systemic manifestations) can be applied to clarify these controversial clinical results.

A previous study demonstrated that SHBG expression levels are higher in the first 12 days of luteal phase compared with the rest of the menstrual cycle ([@b31-ol-0-0-11549],[@b32-ol-0-0-11549]). In both pre-menopause and post-menopause groups, SHBG expression levels decreased with increasing weight. SHBG level was lower in single nulliparous compared with married nulliparous or parous females ([@b31-ol-0-0-11549]). In post-menopause, SHBG increased in the years following menopause ([@b31-ol-0-0-11549]). In the present study of healthy volunteers, a similar trend was revealed as SHBG expression levels exhibited a decreasing trend until age 49 and then an increasing pattern \>50 years. Therefore, it was suggested that the SHBG expression levels must be determined for pre-menopausal and post-menopausal females separately, as the mean SHBG expression levels in these two groups were different ([@b20-ol-0-0-11549]). Serum SHBG expression levels are regulated by a biologically active and unbound hormone fraction, with androgens having an inhibitory effect and estrogens having a stimulatory effect on the SHBG expression levels ([@b1-ol-0-0-11549],[@b16-ol-0-0-11549],[@b33-ol-0-0-11549]). High SHBG expression levels were significantly associated with decreased breast cancer risk and protective function in post-menopausal females ([@b34-ol-0-0-11549]). In the present study, in patients with breast cancer in Groups B and C, the SHBG expression levels indicated a decreasing trend after age 50, although it showed an increasing trend in healthy females aged ≥50 years. Although the patients in this study were mostly younger than Western patients ([@b35-ol-0-0-11549]), receiving mainly chemotherapy instead of hormonal treatment and the healthy volunteers were younger than the patients with cancer, the trend was similar to that in Western patients when the SHBG expression levels was compared by age ([@b14-ol-0-0-11549],[@b15-ol-0-0-11549]). SHBG expression levels were increased by estrogen but decreased by testosterone, suggesting that upregulated SHBG may be an indicator of an estrogenic environment ([@b11-ol-0-0-11549]). Therefore, it was suggested that SHBG expression levels were an improved predictor of hormone treatment compared with the estrogen receptor, as higher SHBG expression levels were identified in ER^+^ patients compared with ER^−^ patients ([@b20-ol-0-0-11549],[@b33-ol-0-0-11549],[@b36-ol-0-0-11549]). Notably, the SHBG expression levels in postmenopausal patients with ER^+^ were higher compared with patients with ER^−^ endometrial and cervical cancer, even if the SHBG level revealed a high overlapping range between ER^+^ and ER^−^ groups ([@b1-ol-0-0-11549]). Whether the considerable overlap of SHBG expression levels between ER^+^ and ER^−^ gynecological cancer is due to other factors, such as heterogeneity of tumor stage, varying degree of illness or weight, needs to be studied in the future ([@b13-ol-0-0-11549]).

A novel biomarker should be an independent predictor of the selected outcome; it must increase the multivariable predictive accuracy of a model ([@b24-ol-0-0-11549]). Despite controversy surrounding the correlation of SHBG with ER status, suggesting that plasma SHBG has little value as a predictive index in breast cancer, Dimou *et al* ([@b37-ol-0-0-11549]) recently reported a potentially causal inverse association between SHBG expression levels and risk of ER positive breast cancer. In the present study, although specificity was good ≥50, the sensitivity was too low in patients with breast cancer to confirm the role of SHBG as a tumor suppressor. SHBG expression levels were not correlated with known tumor markers CA15-3 or CA125. No additive effect of the biomarkers was identified using all three biomarkers for cancer prediction. A larger study using an age-specific reference value with estrogen level may resolve this issue in the future. A non-synonymous single nucleotide polymorphism in exon 8 can result in an amino acid substitution of asparaginase for aspartic acid (D356N, rs6259) in the SHBG protein ([@b38-ol-0-0-11549]). The asparagine allele of SHBG was associated with elevated circulating SHBG in postmenopausal females ([@b38-ol-0-0-11549]). This genotype may be applied in future studies as a biomarker.

Genistein not only increases SHBG expression in Hep-G2 cells, but also suppresses Hep-G2 cell proliferation ([@b2-ol-0-0-11549]). As genistein is an inhibitor of tyrosine-specific protein kinases, isoflavonoid may serve a role in the prevention of malignant tumors, including hormone-dependent cancers in countries with high consumption of soy products, such as Japan and Korea ([@b2-ol-0-0-11549]). Genotyping and diet analysis must be combined in the future to determine the protective role of SHBG in female breast and gynecological cancer.

In conclusion, there was a significant difference in the SHBG expression levels between male and female healthy volunteers. There was also a different pattern in the SHBG expression levels between female healthy volunteers and female patients with breast cancer ≥50 years. Although SHBG itself cannot be used as a biomarker, different reference values stratified by age and sex may help to determine its role in predicting a high-risk group for hormone-dependent cancer, and guide treatment in post-menopausal patients with breast cancer.
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![Different time points when blood was collected for sex hormone-binding globulin measurement during breast cancer progression with different tumor burden. (Group A) Cancer-free state with neo-adjuvant chemotherapy and surgery. (Group B) Initial diagnosis state of locally advance breast cancer. (Group C) High tumor burden state with systemic relapse after surgery.](ol-20-01-0364-g00){#f1-ol-0-0-11549}

![Age distribution of healthy males, healthy females and patients with breast cancer. Age, mean ± standard deviation.](ol-20-01-0364-g01){#f2-ol-0-0-11549}

###### 

Comparison of SHBG expression levels in healthy volunteers and patients with breast cancer. SHBG expression levels presented by: (A) Sex (healthy females, healthy males and total healthy females and males); (B) age by decade in both healthy females and healthy males; (C) pre- and post-menopausal states of healthy females; and (D) patients with breast cancer in different cancer group with different tumor burden. SHBG, sex hormone-binding globulin.
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![Comparison of SHBG expression levels in patients with breast cancer by (A) total patients by age decade, (B) by age in each cancer group with different tumor burden and (C) by menopause state in each cancer group with different tumor burden. Boxplots with maximum and minimum values. Bar represents the median value and dots are outliers. SHBG, sex hormone binding-globulin.](ol-20-01-0364-g06){#f4-ol-0-0-11549}

###### 

Correlation between SHBG and (A) CA15-3 or (B) CA125. SHBG, sex hormone binding-globulin; CA, cancer antigen.
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###### 

Comparison of SHBG levels by sex and age in healthy volunteers.

            Male        Female                                                                                                                
  --------- ----------- ---------------------------------------------------- ----------- ---------------------------------------------------- --------------------------------------------------------
  Range     29.0±11.6   40                                                   46.4±12.8   40                                                   \<0.0001^[a](#tfn2-ol-0-0-11549){ref-type="table-fn"}^
  \<30      20.8±5.1    7                                                    51.2±17.0   11                                                   0.0008^[b](#tfn3-ol-0-0-11549){ref-type="table-fn"}^
  30-39     25.6±7.9    12                                                   44.4±11.3   15                                                   \<0.0001^[a](#tfn2-ol-0-0-11549){ref-type="table-fn"}^
  40-49     36.6±13.1   13                                                   43.8±10.8   11                                                   0.17^[b](#tfn3-ol-0-0-11549){ref-type="table-fn"}^
  ≥50       28.9±11.7   8                                                    48.3±8.8    3                                                    0.05^[b](#tfn3-ol-0-0-11549){ref-type="table-fn"}^
  P-value               0.01^[c](#tfn4-ol-0-0-11549){ref-type="table-fn"}^               0.66^[c](#tfn4-ol-0-0-11549){ref-type="table-fn"}^   

Data were analyzed using an

Independent t-test, a

Wilcoxon rank sum test and a

Kruskal-Wallis test. SHBG, sex hormone binding-globulin; SD, standard deviation.

###### 

Comparison of SHBG levels by menopause state in female healthy volunteers.

                               Serum SHBG level, mean ± SD   Participants, n   P-value
  ---------------------------- ----------------------------- ----------------- ----------------------------------------------------
  Pre-menopause (\<50 years)   46.3±13.2                     37                
  Post-menopause (≥50 years)   48.3±8.8                      3                 0.74^[a](#tfn6-ol-0-0-11549){ref-type="table-fn"}^

SHBG, sex hormone binding-globulin; SD, standard deviation

Kruskal-Wallis test.

###### 

Comparison of SHBG levels by age in different cancer states.

                           Group A                                               Group B   Group C                                                                                                               
  ------------------------ ----------------------------------------------------- --------- ----------------------------------------------------- ---- ----------------------------------------------------- ---- ----------------------------------------------------
  All patients             47.3±23.7                                             37        49.1±32.2                                             32   51.4±29.0                                             40   0.86^[a](#tfn8-ol-0-0-11549){ref-type="table-fn"}^
  30-39                    49.5±25.4                                             13        51.9±24.2                                             11   49.9±23.0                                             9    0.97^[b](#tfn9-ol-0-0-11549){ref-type="table-fn"}^
  40-49                    53.3±28.0                                             7         57.9±48.2                                             7    51.9±32.0                                             14   0.85^[a](#tfn8-ol-0-0-11549){ref-type="table-fn"}^
  ≥50                      43.2±21.0                                             17        42.4±29.1                                             14   51.8±30.9                                             17   0.55^[b](#tfn9-ol-0-0-11549){ref-type="table-fn"}^
  P-value                  0.72^[a](#tfn8-ol-0-0-11549){ref-type="table-fn"}^              0.59^[a](#tfn8-ol-0-0-11549){ref-type="table-fn"}^         0.94^[a](#tfn8-ol-0-0-11549){ref-type="table-fn"}^         
                                                                                                                                                                                                                 
  **B, menopause state**                                                                                                                                                                                         
                                                                                                                                                                                                                 
  Pre-menopause            50.8±25.7                                             20        54.3±34.2                                             18   51.1±28.3                                             23   0.98^[a](#tfn8-ol-0-0-11549){ref-type="table-fn"}^
  Post-menopause           43.2±21.0                                             17        42.4±29.1                                             14   51.8±30.9                                             17   
  P-value                  0.33^[c](#tfn10-ol-0-0-11549){ref-type="table-fn"}^             0.33^[d](#tfn11-ol-0-0-11549){ref-type="table-fn"}^        0.93^[d](#tfn11-ol-0-0-11549){ref-type="table-fn"}^        0.62

Data were analyzed using a

Kruskal-Wallis test

ANOVA, an

Independent t-test and a

Wilcoxon rank sum test. SHBG, sex hormone binding-globulin; SD, standard deviation.

###### 

Comparison of SHBG positivity in each decade of age in breast cancer.

  Biomarker               Sensitivity, %   Specificity, %   Accuracy, %
  ----------------------- ---------------- ---------------- -------------
  Total (n=109)           36               65               46
  --39 (n=33)             35               54               42
  --49 (n=28)             52               71               57
  ≥50 (n=48)              26               71               42
  Pre-menopause (n=61)    44               60               50
  Post-menopause (n=48)   26               71               42

###### 

Comparison of sensitivity, specificity and accuracy of 3 biomarkers in breast cancer.

  Biomarker                Sensitivity, %   Specificity, %   Accuracy, %
  ------------------------ ---------------- ---------------- -------------
  CA15-3                   61               82               68
  CA125                    51               65               56
  CA15-3 and CA125         75               59               70
  CA15-3, CA125 and SHBG   79               32               64
